Browse by Author O'Brien, SG
|
|
|
|
|
| Title | Author(s) | Year | View Count |
 | Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia | Le Coutre, P; Ottmann, OG; Giles, F; Kim, DW; Cortes, J; Gattermann, N; Apperley, JF; Larson, RA; Abruzzese, E; O'Brien, SG; Kuliczkowski, K; Hochhaus, A; Mahon, FX; Saglio, G; Gobbi, M; Kwong, YL; Baccarani, M; Hughes, T; Martinelli, G; Radich, JP; Zheng, M; Shou, Y; Kantarjian, H | 2008 | 123 |
|
|
|
|
